Tyra Biosciences develops clinical-stage precision medicines that target Fibroblast Growth Factor Receptor (FGFR) biology. News about TYRA commonly centers on its SNÅP drug-design platform, oral dabogratinib as an FGFR3-selective inhibitor, and pipeline programs in targeted oncology and genetically defined conditions.
Recurring updates include financial results, scientific conference presentations, clinical-study progress in urologic cancers, achondroplasia, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and governance or leadership changes. Company announcements also cover investor-conference participation and program descriptions for TYRA-430 and TYRA-200.
Tyra Biosciences (Nasdaq: TYRA) reported Q4 and full‑year 2025 results and outlined its "dabogratinib 3x3" strategy targeting LG‑UTUC, IR NMIBC and achondroplasia. TYRA holds $256.0 million in cash and marketable securities, with a stated runway through at least 2027. Key near‑term clinical catalysts: SURF302 interim data by end 1H 2026 and BEACH301 safety sentinel results in 2H 2026; SURF303 first patient expected in 2026. Full‑year R&D rose to $102.9M and net loss widened to $119.9M.
Tyra Biosciences (NASDAQ: TYRA) announced two poster presentations at the 2026 ASCO Genitourinary (GU) Cancers Symposium, held February 26-28, 2026 in San Francisco.
Posters on dabogratinib (formerly TYRA-300) include ctDNA monitoring in metastatic urothelial cancer (Abstract 809) and a SURF302 Phase 2 trial in non-muscle invasive bladder cancer (TPS886), both presented February 27, 2026 at 11:30 AM–12:45 PM PST. Posters will be posted on TYRA's investor relations website after the presentations.
Tyra Biosciences (Nasdaq: TYRA) will participate in multiple investor conferences between Feb 26 and Mar 12, 2026, including virtual and in-person presentations and one-on-one meetings.
Key events: Oppenheimer Life Sciences (virtual chat) on Feb 26, 2026; TD Cowen (hybrid) on Mar 4, 2026 in Boston; and multiple Miami conferences March 8–12 with webcasts and replays available on the company's investor site.
Tyra Biosciences (Nasdaq: TYRA) appointed Bhavesh Ashar as Chief Operating Officer (effective immediately) and Heather Faulds as Chief Regulatory Officer (effective December 8, 2025).
Both hires bring senior pharmaceutical experience: Mr. Ashar has 25+ years including chief commercial roles and launches of OGSIVEO and GOMEKLI; Ms. Faulds has 20+ years leading global regulatory strategy and was involved in approvals including SPINRAZA and LYBALVI. They will support advancement of oral dabogratinib through global Phase 2 studies in skeletal dysplasia and urologic cancers and preparation for potential Phase 3 programs.
Tyra Biosciences (Nasdaq: TYRA) announced management will participate in investor events in November–December 2025, including a hybrid presentation at the Jefferies London Healthcare Conference and one-on-one meetings at the 37th Annual Piper Healthcare Conference.
Jefferies presentation: Wednesday, November 19, 2025 at 4:00 PM GMT (hybrid slides & moderated Q&A) in London, UK; a live webcast will be available on Tyra Biosciences' For Investors page and replayed after the event. Piper conference meetings: December 2–4, 2025 in New York, NY.
Tyra Biosciences (Nasdaq: TYRA) reported Q3 2025 results and clinical progress on November 5, 2025. Key clinical updates: TYRA dosed first patients with dabogratinib in BEACH301 (achondroplasia) and SURF302 (FGFR3-altered IR NMIBC), advanced development into LG-UTUC with an IND cleared by the FDA, and expects interim Phase 2 readouts in 2026.
Financials: TYRA held $274.9 million in cash, cash equivalents and marketable securities as of September 30, 2025, providing runway through at least 2027. Q3 R&D was $25.5M, G&A $7.5M, and net loss $29.9M.
Tyra Biosciences (Nasdaq: TYRA) has announced a significant milestone in its BEACH301 Phase 2 clinical study, with the first child being dosed with dabogratinib (TYRA-300) for treating achondroplasia, the most common form of dwarfism.
Dabogratinib is positioned as the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, which affects approximately 250,000 individuals worldwide. The drug targets the FGFR3 G380R mutation, present in 99% of achondroplasia cases. Initial results from the safety sentinel cohort are expected in 2H 2026.
The study aims to evaluate the safety and efficacy of this once-daily oral treatment, developed using TYRA's proprietary SNÅP platform, offering a potentially more accessible treatment option for children with achondroplasia.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in two upcoming investor events.
The company will participate in a fireside chat at the Virtual H.C. Wainwright "HCW@Home" series on August 21, 2025, at 11 AM ET. Additionally, management will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9 AM ET in New York, featuring a fireside chat and one-on-one investor meetings.
Webcasts of both events will be accessible through Tyra's investor relations website.
Tyra Biosciences (NASDAQ: TYRA) reported Q2 2025 financial results and significant progress in its clinical programs. The company maintains a strong financial position with $296.3 million in cash and equivalents, providing runway through 2027. Key developments include dosing the first patient in SURF302, a Phase 2 study evaluating dabogratinib for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC).
The company reported a net loss of $28.1 million for Q2 2025, with R&D expenses of $24.3 million and G&A expenses of $7.1 million. TYRA is advancing multiple clinical programs, including BEACH301 for achondroplasia, SURF431 for hepatocellular carcinoma, and SURF201 for intrahepatic cholangiocarcinoma. Important upcoming milestone includes topline data from SURF302 expected in 1H 2026.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in a virtual fireside chat at the UBS Biotech Management Live Call Series.
The event, focused on achondroplasia and growth disorders, will take place on July 25, 2025, at 11 am ET. Key participants include CEO Todd Harris, CMO Doug Warner, MD, and CFO Alan Fuhrman, with UBS SMID Cap Biotechnology Analyst Ellie Merle hosting the discussion.